Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:CASC

(CASC) (CASC) Stock Price, News & Analysis

(CASC) logo

About (CASC) Stock (NASDAQ:CASC)

Advanced Chart

Key Stats

Today's Range
$10.02
$10.02
50-Day Range
N/A
52-Week Range
$3.18
$10.21
Volume
N/A
Average Volume
1.09 million shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Cascadian Therapeutics, Inc., formerly Oncothyreon Inc., is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutic products for the treatment of cancer. The Company's clinical-stage product candidate includes ONT-380, an orally active and selective small-molecule human epidermal growth factor receptor (HER) 2 inhibitor. The Company's ONT-10 is a therapeutic vaccine targeting the Mucin 1 peptide antigen (MUC1). The Company is engaged in developing preclinical product candidates in oncology using its Checkpoint kinase 1 (Chk1) kinase inhibitor and protocell technology. The Company completed the evaluation of approximately two dosing cohorts in its Phase Ib trial of ONT-10 in combination with the anti-CD27 T-cell agonist antibody varlilumab in collaboration with other company. The Company has completed Phase I trial of ONT-380, with both dose-escalation and expansion components. The Company has initiated Phase Ib trials of ONT-380.

Receive CASC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for (CASC) and its competitors with MarketBeat's FREE daily newsletter.

CASC Stock News Headlines

Everyone’s watching Nvidia right now. Here’s why I’m excited.
So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal with Saudi Arabia to power its new AI empire 🤯 We’re talking about hundreds of thousands of chips, including their latest Grace Blackwell supercomputer.
See More Headlines

CASC Stock Analysis - Frequently Asked Questions

(CASC) (NASDAQ:CASC) announced its quarterly earnings data on Wednesday, November, 8th. The biopharmaceutical company reported ($0.28) earnings per share for the quarter, beating the consensus estimate of ($0.29) by $0.01.

Based on aggregate information from My MarketBeat watchlists, some other companies that (CASC) investors own include Xtrackers California Municipal Bond ETF (CA), Endologix (ELGX), BlackRock (BLK), Athabasca Oil (ATH), Chipotle Mexican Grill (CMG), Aegean Marine Petroleum Network (ANW) and NIC (EGOV).

Company Calendar

Last Earnings
11/08/2017
Today
6/05/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
N/A
Industry
N/A
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:CASC
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

This page (NASDAQ:CASC) was last updated on 6/6/2025 by MarketBeat.com Staff
From Our Partners